Who invests in ADPKD

By Dalya Gartzman, Renasis Bio · · Data as of 26 Oct 2026

167 investors backed ADPKD companies over the past decade. 12 backed two.

Including:

Additional investments from top-tier VCs: ARCH Venture Partners, OrbiMed, Versant Ventures, Frazier Life Sciences.

And a telling one: Otsuka, the maker of tolvaptan, the only approved ADPKD drug, joined SonoThera's Series B in 2026.

Who

Claude and I mapped who backs ADPKD drug developers. Of about 40 companies with ADPKD programs, 25 have private funding we could trace: 167 investors across 54 rounds.

Figure 1: Every ADPKD funding round since 2013. 25 companies, 54 rounds, one row per company, one bubble per round; bubble size is the round size and color the round stage. Bars above show disclosed dollars per year, peaking at $547M in 2024, with about $295M so far in 2026.
Figure 1. Every ADPKD funding round since 2013. Explore it in the investors map
Figure 2: 12 of 167 investors backed two ADPKD companies: Atlas Venture, 3E Bioventures Capital, F-Prime Capital, Johnson & Johnson Innovation (JJDC), New Alliance Capital, NKF Innovation Fund, RA Capital Management, Roche Venture Fund, Westlake Village BioPartners, DCI Partners, SymBiosis and Tohoku University Venture Partners, linked to 15 of 25 companies. Also in ADPKD with one company each: ARCH Venture Partners, OrbiMed, Versant Ventures, Frazier Life Sciences. Otsuka, the maker of tolvaptan, joined SonoThera's 2026 Series B.
Figure 2. The 12 investors in two ADPKD companies. Explore them in the investors map (filter: only investors in 2+ ADPKD companies)

Why

📈 The last three years brought more money and more investors than the decade before them: $0.85B in 2013–2023, $1.04B since.

What happened in 2023 to set this up? Three candidates, in order:

  1. Kidney became an M&A story. Novartis bought Chinook for $3.5B (Aug 2023), then Regulus for up to $1.7B (2025).
  2. Vertex moved in. Its PKD1 corrector VX-407 entered the clinic in 2024.
  3. Tolvaptan hit its peak and then went generic. $1.47B in US sales in 2024; first generic in 2025.

🇯🇵 Japan, tolvaptan's home country, is a great illustration of this trend. Two Japan-based biotechs, Rege Nephro and Scohia, have drawn 37 investors, and 22(!) of them have joined since 2024, as the drug peaked and went generic.

Figure 3: First-time ADPKD investors per year, 2013 to 2026. 74 of 167 made their first ADPKD bet in 2024 to 2026: 27 in 2024, 14 in 2025 and 33 in 2026 (January to October), against 32 in 2022 and 10 in 2023. Markers: August 2023, Novartis closes the $3.5B Chinook deal; March 2024, FDA clears Vertex VX-407 for ADPKD; April 2025, first US generic tolvaptan approved.
Figure 3. First-time ADPKD investors per year. Explore them in the investors map

What

🎯 The new money is going after the root cause:

Figure 4: Companies aiming to restore polycystin (PC1 or PC2) directly, one dot per company at the year of its first funding round. 2 of 11 companies first funded before 2022, and 8 of 14 first funded in 2022 or later. Restoring polycystin: Helex, Arnatar, Torque Bio, Estuary, Renasant, Silver Spur, Renasis Bio. Likely, target not yet public (all genetic medicines): Nephrogen, SonoThera, Borealis.
Figure 4. Companies aiming to restore polycystin, by first funding year. Explore them in the investors map

When

Across biotech, investors are playing it safe: in 2024–2025, only ~37% of venture dollars went to seed and Series A rounds. The rest went to later-stage companies.

🌱 ADPKD flips that. Since 2024, ~66% of ADPKD venture dollars went to seed and Series A rounds, like a $54.5M seed for Renasant Bio, a $93M Series A for Estuary and a $150M Series A for Borealis, all for programs still in preclinical.

Figure 5: Share of venture dollars by round stage. All biotech, 2024 to September 2025 (J.P. Morgan / DealForma): 37% to seed and Series A, 63% to Series B and later. ADPKD, 2024 to 2026, 15 disclosed rounds totaling $1.04B: 66% to seed and Series A, 34% later. The 15 rounds, largest first: Gondola Bio launch $300M (2024), Borealis Series A $150M (2024), SonoThera Series B $125M (2026), Estuary Series A $93M (2026), Alebund Series C $77M (2025), Alebund pre-IPO $60.6M (2025), Renasant seed $54.5M (2025), Arnatar Series A $52M (2024), Mironid Series B $46M (2026), Borealis Series A extension $30M (2024), Scohia later round $20.1M (2026), Rege Nephro Series B $15M (2024), Rege Nephro pre-Series C $10.6M (2026), Helex seed $3.5M (2025), Renasis Bio early round $0.96M (2025, estimated).
Figure 5. Share of venture dollars to seed and Series A rounds: all biotech vs ADPKD. Explore the rounds in the investors map

To sum up

ADPKD is drawing serious investor interest, backing both established and novel modalities.

Most importantly, that means more shots on goal for patients, who today have just one approved drug, which does not treat the root cause and has severe side effects.

It also gives me hope for biotech more broadly: focused niches let single assets prove out whole platforms. At Renasis Bio, we strive to be in this group - having ADPKD as our lead program, spearheading our pipeline of RNA-upregulating small molecules.

Sources